REGENXBIO Inc. (RGNX)
RGNX Stock Price Chart
Explore REGENXBIO Inc. interactive price chart. Choose custom timeframes to analyze RGNX price movements and trends.
RGNX Company Profile
Discover essential business fundamentals and corporate details for REGENXBIO Inc. (RGNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Sept 2015
Employees
353.00
Website
https://www.regenxbio.comCEO
Curran Simpson
Description
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RGNX Financial Timeline
Browse a chronological timeline of REGENXBIO Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.22, while revenue estimate is $106.91m.
Earnings released on 14 May 2026
EPS came in at -$1.72 falling short of the estimated -$1.36 by -26.47%, while revenue for the quarter reached $6.39m , missing expectations by -75.26%.
Earnings released on 5 Mar 2026
EPS came in at -$1.30 falling short of the estimated -$1.01 by -28.71%, while revenue for the quarter reached $30.34m , missing expectations by -30.99%.
Earnings released on 6 Nov 2025
EPS came in at -$1.20 surpassing the estimated -$1.38 by +13.04%, while revenue for the quarter reached $29.73m , missing expectations by -49.83%.
Earnings released on 7 Aug 2025
EPS came in at -$1.38 falling short of the estimated -$1.13 by -22.12%, while revenue for the quarter reached $21.36m , missing expectations by -80.59%.
Earnings released on 12 May 2025
EPS came in at $0.12 falling short of the estimated $0.41 by -70.73%, while revenue for the quarter reached $89.01m , missing expectations by -15.51%.
Earnings released on 13 Mar 2025
EPS came in at -$1.01 surpassing the estimated -$1.27 by +20.47%, while revenue for the quarter reached $21.21m , missing expectations by -10.51%.
Earnings released on 6 Nov 2024
EPS came in at -$1.17 falling short of the estimated -$1.16 by -0.86%, while revenue for the quarter reached $24.20m , beating expectations by +3.20%.
Earnings released on 1 Aug 2024
EPS came in at -$1.05 surpassing the estimated -$1.29 by +18.60%, while revenue for the quarter reached $22.30m , missing expectations by -8.36%.
Earnings released on 8 May 2024
EPS came in at -$1.38 falling short of the estimated -$1.28 by -7.81%, while revenue for the quarter reached $15.62m , missing expectations by -33.58%.
Earnings released on 27 Feb 2024
EPS came in at -$1.43 falling short of the estimated -$1.27 by -12.60%, while revenue for the quarter reached $22.21m , missing expectations by -34.67%.
Earnings released on 8 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.44 by +2.08%, while revenue for the quarter reached $28.91m , missing expectations by -19.88%.
Earnings released on 2 Aug 2023
EPS came in at -$1.66 falling short of the estimated -$1.26 by -31.75%, while revenue for the quarter reached $19.98m , missing expectations by -42.10%.
Earnings released on 3 May 2023
EPS came in at -$1.53 falling short of the estimated -$1.52 by -0.66%, while revenue for the quarter reached $19.14m , missing expectations by -37.46%.
Earnings released on 28 Feb 2023
EPS came in at -$1.38 surpassing the estimated -$1.48 by +6.76%, while revenue for the quarter reached $31.35m , missing expectations by -16.30%.
Earnings released on 3 Nov 2022
EPS came in at -$1.75 falling short of the estimated -$1.55 by -12.90%, while revenue for the quarter reached $26.51m , missing expectations by -13.96%.
Earnings released on 3 Aug 2022
EPS came in at -$1.58 falling short of the estimated -$1.44 by -9.72%, while revenue for the quarter reached $32.65m , beating expectations by +15.31%.
Earnings released on 4 May 2022
EPS came in at -$1.62 falling short of the estimated -$1.29 by -25.58%, while revenue for the quarter reached $22.22m , missing expectations by -18.37%.
Earnings released on 1 Mar 2022
EPS came in at $6.67 surpassing the estimated $4.71 by +41.61%, while revenue for the quarter reached $398.66m , missing expectations by -6.82%.
Earnings released on 2 Nov 2021
EPS came in at -$1.37 falling short of the estimated -$0.87 by -57.47%, while revenue for the quarter reached $30.77m , missing expectations by -2.28%.
Earnings released on 9 Aug 2021
EPS came in at -$1.36 falling short of the estimated -$1.08 by -25.93%, while revenue for the quarter reached $22.04m , missing expectations by -24.07%.
RGNX Stock Performance
Access detailed RGNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
